Market Overview

UPDATE: Piper Jaffray Upgrades Cepheid Following In-Line 2Q13 Results

Share:
Related CPHD
US Stock Futures Rise Ahead Of Earnings, Economic Data
Cepheid Announces European Approval of Xpert HCV Viral Load
Cepheid's (CPHD) Xpert HIV-1 Qual Test Gets CE-IVD Mark - Analyst Blog (Zacks)

In a report published Friday, Piper Jaffray analyst William R. Quirk upgraded Cepheid (NASDAQ: CPHD) from Neutral to Overweight, and raised the price target from $37.00 to $43.00.

In the report, Piper Jaffray noted, “Cepheid reported 2Q13 results in-line with the preliminary announcement. Encouragingly, management resolved its recent manufacturing-related allocation issues and investments to improve manufacturing are a priority. Management increased F2013 revenue guidance to $380M-$385M (was $375M-$385M), but lowered its EPS outlook to reflect the inventory charge and additional manufacturing operations investments (now ($0.30)-($0.27), was ($0.05)-$0.01). We are upgrading CPHD shares to Overweight from Neutral with a $43 price target (was $37) based on ~7x (was 6x) CY14E CDx revenue + ~1.5x CY14E base revenue. We suspect competitive noise heading into/during the upcoming AACC meeting could create some share price volatility, but view CMS' upcoming Hospital IQR decision (potentially adding MRSA & C. diff as new chart abstracted HAI measures for FY16) and viral load (FY14 U.S., FY15 U.S.) as significant potential catalysts, justifying our higher multiple and price target.”

Cepheid closed on Thursday at $34.14.

Latest Ratings for CPHD

DateFirmActionFromTo
Dec 2014Bank of AmericaUpgradesNeutralBuy
Dec 2014CitigroupMaintainsBuy
Dec 2014OppenheimerMaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Piper Jaffray William R. QuirkAnalyst Color Upgrades Analyst Ratings

 

Related Articles (CPHD)

Around the Web, We're Loving...